<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772756</url>
  </required_header>
  <id_info>
    <org_study_id>2018-139-01</org_study_id>
    <nct_id>NCT03772756</nct_id>
  </id_info>
  <brief_title>EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma</brief_title>
  <official_title>Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Unresectable Pancreatic Adenocarcinoma - a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First People's Hospital of Hangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a
      prospective randomised trial in patients with inoperable PDAC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The five year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite
      of the advances in management of cancers in the last few decades. Endobiliary application of
      radiofrequency ablation (RFA) has been developed in our unit and used in patients with
      unresectable bile duct and pancreatic head adenocarcinomas presenting with biliary
      obstruction. Various techniques of EUS-guided tumour ablation have been described, including
      RF ablation, photodynamic therapy, laser ablation, and ethanol injection. Endoscopic
      ultrasound guided RFA (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter through a
      19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis
      .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tumour size as measured on EUS and or CT</measure>
    <time_frame>60 days</time_frame>
    <description>The tumor size was compared before and after 60 days EUS-RFA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum levels of Ca 19-9</measure>
    <time_frame>60 days</time_frame>
    <description>Serum levels of Ca 19-9 was compared before and after 60 days EUS-RFA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Survival rate 6 months after EUS-RFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Survival rate 12 months after EUS-RFA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatic Adenocarcinoma Non-resectable</condition>
  <arm_group>
    <arm_group_label>EUS-RFA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in EUS-RFA group will undergo endoscopic ultrasound guided radiofrequency ablation(EUS-RFA ) and chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the control group will receive chemoradiotherapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic ultrasound guided radiofrequency ablation</intervention_name>
    <description>Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.</description>
    <arm_group_label>EUS-RFA group</arm_group_label>
    <other_name>EUS-RFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chemoradiotherapy</intervention_name>
    <description>Receive chemoradiotherapy</description>
    <arm_group_label>EUS-RFA group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in the age group 20 to 80 years

          -  A cytological or histological diagnosis of inoperable PDAC based on multidisciplinary
             review of cross sectional imaging and cytology or histology results.

          -  Patients who have been deemed unfit for surgical resection of the PDAC subjects who
             are fit for surgical resection but have declined surgery will also be considered for
             the study

          -  PDAC patients presenting with jaundice to be considered after a successful biliary
             drainage

          -  Patients ought to be fit enough to be considered for the study (ECOG performance
             status 0, 1 or 2)

          -  Patients capable of giving informed consent

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Pregnancy or breast feeding

          -  ECOG performance status 3 or 4

          -  Life expectancy less than 3 months

          -  Patients with distant metastases or malignant ascites
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofeng Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>First People's Hospital of Hangzhou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianfeng Yang, M.D</last_name>
    <phone>+8613454132186</phone>
    <email>yjf-1976@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jianfeng Yang</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Yang</last_name>
      <phone>+8613454132186</phone>
      <email>yjf-1976@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>31006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Yang, M.D</last_name>
      <phone>+86-0571-56006999</phone>
      <email>yjf-1976@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yang Wang, M.S</last_name>
      <phone>+86-0571-56006996</phone>
      <email>wy8124@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gaidhane M, Smith I, Ellen K, Gatesman J, Habib N, Foley P, Moskaluk C, Kahaleh M. Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of the Pancreas in a Porcine Model. Gastroenterol Res Pract. 2012;2012:431451. doi: 10.1155/2012/431451. Epub 2012 Sep 20.</citation>
    <PMID>23049547</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 9, 2018</study_first_submitted>
  <study_first_submitted_qc>December 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First People's Hospital of Hangzhou</investigator_affiliation>
    <investigator_full_name>Jianfeng Yang</investigator_full_name>
    <investigator_title>Associate director of gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>Endoscopic ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

